Herpes simplex virus (HSV) encephalitis (HSVE) is the commonest cause of death in cases of sporadic encephalitis in humans (Johnston, 1998) with relapse occurring in approximately 12% of patients (Skoldenberg et al. 2006). While commonly attributed to viral reactivation, it is increasingly recognised that a proportion of ‘relapses’ are due to anti-NMDA receptor encephalitis (NMDARE), a treatable autoimmune disorder caused by IgG autoantibodies against the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor (Armanygue et al. 2015). While the proportion of clinical relapses from HSVE attributable to NMDARE remains unknown, a study found 25% of HSVE patients had anti-NMDA receptor antibodies in CSF after three months (Westman et al. 2016). Affective symptoms have been described as a presenting symptom of HSVE, as well as a sequel (McGrath et al. 1997), although the underlying mechanisms have not been elucidated. We report the case of a manic episode associated with transient NMDA receptor autoimmunity occurring as a sequel to HSVE.

A 37-year-old male with an unremarkable medical history was admitted to hospital with headaches and subsequently suffered a generalised seizure and cardio-respiratory arrest. MRI revealed acute restricted diffusion in the right mesial temporal lobe and a cerebrospinal fluid (CSF) sample was positive for HSV type 1 (HSV-1). He was treated with intravenous acyclovir and discharged with residual symptoms of headache, fatigue and bilateral tremor of the upper limbs.

One month later he was brought back to the hospital with a 4-day history of paranoia and insomnia. On arrival he was distractible and preoccupied with colours and numbers and highly agitated, requiring intramuscular sedation. Neurological examination revealed gaze inattention and saccadic intrusion of smooth pursuit, fine tremor with superimposed myoclonic jerks and subtle perioral myoclonus. The neuropsychiatric assessment revealed manic symptoms including social disinhibition, elation, increased self-esteem and tangential thoughts.

Initial blood results revealed elevated C-reactive protein (23 mg/L) and neutrophil count (7.9 × 10⁹/L). Serum anti-NMDA receptor antibody using a live cell-based assay was low positive (scoring 1.5 on a 0–4 scale at 1 : 20 dilution and 0.5 at 1 : 100 dilution). Serum anti-VGKC and onconeural antibody screen were negative. CSF revealed elevated protein (784 mg/dL) and white blood cells (9 cells/μL). The case expands the likely clinical manifestations of post-HSVE NMDA receptor autoimmunity, as well as suggesting a plausible explanation for some of the cognitive and affective changes occurring after HSVE.

Evidence supporting the pathogenic relevance of NMDA receptor autoimmunity includes the characteristic delta brush-like waves, unmatched oligoclonal bands and temporal association between the antibody and affective status. Possible mechanisms by which HSV infection could cause neuronal autoimmunity include (a) limbic damage leading to exposure of NMDA receptor epitopes triggering a second immune response and (b) molecular mimicry. An alternative...
explanation is that the patient’s neuropsychiatric symptoms emerged as a sequel to structural damage from HSV infection and the autoantibodies reflect an epiphenomenon, although this would not account for the delayed and transient nature of the manic episode.

Leypoldt et al. (2013) reported a case of NMDARE following HSVE, who presented with predominantly manic symptoms, and who recovered with steroid treatment. Notably, our patient did not receive immunotherapy but recovered as serum anti-NMDA receptor antibodies became undetectable. The incidence of psychosis and mania is greatly increased following encephalitis (Granerod et al. 2017). Mechanisms underlying the development of postencephalitic psychiatric disorders are likely to be heterogeneous, however, we suggest CNS autoimmunity should be considered a potential aetiological factor.

Within psychiatry, there has been a recent interest in the role of NMDA receptor autoimmunity in ‘primary’ psychiatric disorders (Al-Diwani et al. 2017); specifically, a temporal association between NMDAR (NR2) antibody level and mania has been reported in the context of bipolar affective disorder (Dickerson et al. 2012). It is notable that evidence of HSV infection in bipolar affective disorder is associated with poor cognitive function (Dickerson et al. 2004). Future research is indicated to explore whether NMDA receptor autoimmunity may be a mechanistic ‘missing link’ connecting HSV infection and cognitive/affective symptoms in psychiatric disorders, including bipolar affective disorder.

This case suggests that patients developing mood symptoms, and in particular mania, following HSV encephalitis should be investigated with NMDA receptor autoantibody testing.

Fig. 1. EEG and MRI on day 5 of admission (left) and at follow up (right) with the time course of events. (a) EEG showing dominant posterior reactive alpha background rhythm at 10–11 Hz. In addition, there are frequent runs of right temporal delta waves, with superimposed serrated activity in the alpha and beta range of delta brush-like appearance which resolved at follow-up 24 weeks later. Spectral analysis over highlighted segment demonstrating power predominantly in the beta, alpha and delta frequency bands. (b) Coronal Fluid Attenuation Inversion Recovery Sequences (FLAIR) and axial T2 showing initial swelling and signal hyper-intensity within the right temporal lobe which reduced at follow-up 15 weeks later, with persisting chronic encephalomalacia in the anterior right temporal lobe. (c) Timeline of events from initial presentation including hospital admission, treatment, Herpes Simplex Virus (HSV) and anti-N-methyl-D-aspartate receptor (NMDAR) antibody status. Also plotted are total Positive and Negative Symptom Scale (PANSS), Young Mania Rating Scale (YMRS), and Addenbrooke’s Cognitive Examination-Revised (ACE-R) scores.
Acknowledgements. The authors thank Dr Agirre-Arrizubieta for independently reviewing the EEG and the Oxford Clinical Neuroimmunology laboratory at the John Radcliffe Hospital Oxford, UK for performing autoantibody testing. The authors also thank the patient for his permission to publish the case.

Financial disclosures. Dr Blackman was supported by an academic clinical fellowship from the NIHR and he reports no conflicts of interest. Dr Pollak was supported by a clinical research training fellowship grant from the Wellcome Trust (no. 105758/Z/14/Z) and he reports no conflicts of interest. Dr Moran, Dr Silber, Dr Symeon, Dr Brunnhuber, Dr Mazumder and Dr Jaffer report no relevant financial interests or potential conflicts of interest.

References